Back to top
more

Clover Health Investments (CLOV)

(Delayed Data from NSDQ)

$2.78 USD

2.78
7,403,773

-0.11 (-3.81%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $2.81 +0.03 (1.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Indrajit Bandyopadhyay headshot

Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?

by Indrajit Bandyopadhyay

CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.

Zacks Equity Research

Centene Pulls 2025 Guidance as Marketplace Growth Falters

by Zacks Equity Research

CNC pulls its 2025 forecast after a $1.8B risk adjustment shortfall. Also, weak Marketplace growth shakes investor confidence.

Zacks Equity Research

Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment

by Zacks Equity Research

CI to cover RhinAer for chronic rhinitis starting Sept. 15, expanding access to a minimally invasive, office-based treatment.

Zacks Equity Research

Here's Why MOH Shares Are Attracting Prudent Investors Now

by Zacks Equity Research

Molina Healthcare draws investor interest with strong earnings growth, contract wins and premium revenue momentum despite rising costs.

Zacks Equity Research

Ensign Enhances Presence With 3 New Acquisitions in 2 States

by Zacks Equity Research

ENSG adds three skilled nursing facilities in Idaho and California, boosting its U.S. footprint and fueling future growth.

Zacks Equity Research

Here's Why You Should Hold Cigna Stock in Your Portfolio for Now

by Zacks Equity Research

CI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.

Zacks Equity Research

Here's Why You Should Add Pediatrix Medical to Your Portfolio Now

by Zacks Equity Research

MD rises 5.6% YTD as earnings beat, hospital deals and lower costs drive growth. The Zacks Rank #2 signals strong near-term prospects.

Zacks Equity Research

Here's Why Encompass Health Shares Are Attracting Investors Now

by Zacks Equity Research

EHC stock jumps 28.8% YTD as investors rally behind strong earnings beat, raised 2025 guidance and a growing national rehab hospital footprint.

Zacks Equity Research

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks Equity Research

All You Need to Know About Clover Health Investments (CLOV) Rating Upgrade to Strong Buy

by Zacks Equity Research

Clover Health Investments (CLOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 171.43% and 3.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Watch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss?

by Debanjana Dey

MedTech companies' quarterly results are likely to reflect strength in customer demand. Let's see how FMS, MASI and CLOV are placed ahead of their earnings releases.

Zacks Equity Research

CLOV Q4 Earnings Beat Estimates, Sales Miss, Membership Rises

by Zacks Equity Research

Clover Health's fourth-quarter 2024 results continue to benefit from the strength of its strong member retention. Strong revenue outlook bodes well.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Tops Q4 Earnings Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 128.57% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Medpace (MEDP) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Debanjana Dey headshot

4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run

by Debanjana Dey

Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.

Zacks Equity Research

Here's Why Clover Health Investments (CLOV) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

The Zacks Analyst Blog Highlights Inspire Medical, Omnicell, Talkspace, Butterfly Network and Clover Health

by Zacks Equity Research

Inspire Medical, Omnicell, Talkspace, Butterfly Network and Clover Health are included in this Analyst Blog.

Nalak Das headshot

5 Medical Info System Stocks to Buy for a Stable Portfolio in 2025

by Nalak Das

Five medical info systems stocks have strong potential for 2025. These are: INSP, OMCL, TALK, BFLY, CLOV.

Zacks Equity Research

Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how CareDx (CDNA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks Equity Research

Down -26.32% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround

by Zacks Equity Research

Clover Health Investments (CLOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Down -25.82% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Clover Health Investments (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised

by Zacks Equity Research

Clover Health's third-quarter 2024 results continue to benefit from the strength of its business model.